Baricitinib plus remdesivir shows promise in hospitalized patients

Dec 14, 2020 - 03:18 PM
FDA product update

Combining the anti-inflammatory drug baricitinib with the antiviral drug remdesivir reduced the median recovery time for hospitalized COVID-19 patients from eight to seven days, according to clinical trial results published Friday in the New England Journal of Medicine.

The therapy appeared to benefit patients requiring high-flow oxygen or non-invasive ventilation most, reducing their median time to recovery from 18 days to 10 days, researchers said.

The clinical trial is the second in the National Institutes of Health Adaptive COVID-19 Treatment Trial, a study to evaluate therapeutics for people hospitalized with COVID-19. 

The Food and Drug Administration last month authorized the emergency use of baricitinib in combination with remdesivir to treat suspected or laboratory confirmed COVID-19 in certain hospitalized patients requiring supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation.

Related News Articles

Headline
CDC releases 2025-26 respiratory disease season outlook
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…
Headline
OSHA extends comment period on proposal removing remaining COVID-19 emergency temporary standard requirements
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…
Headline
CDC says COVID-19 cases growing or likely growing in 45 states 
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Headline
FDA announces recall of cefazolin by Sandoz for mislabeling
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
COVID-19 vaccination approved for older adults and high-risk, younger children
 The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
OSHA proposes removing remaining requirements of its COVID-19 emergency temporary standard
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…